Pfizer, Inc. · NYSE:PFE
Pfizer — 40th Annual J.P. Morgan Healthcare Conference 2022
25 slides from Pfizer's conference presentation, Jan 10, 2022
Slide 1: Advancing Our mRNA Strategic Development
Advancing Our mRNA Strategic Development 40th Annual JP Morgan HealthCare Conference Albert Bourla, DVM, PhD CEO & Chairman January 10, 2022 Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 1
Slide 2: Forward-Looking Statements and Other Notices
Forward-Looking Statements and Other Notices This presentation includes forward-looking statements about, among other topics, Pfizer's mRNA strategy and pipeline portfolio; Pfizer’s collaboration agreement with BioNTech to co-develop a shingles mRNA vaccine; Pfizer’s collaboration with Beam Therapeu
Slide 3: Pfizer's mRNA Strategy
Pfizer’s mRNA Strategy Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 3
Slide 4: mRNA is expected to be one of our sustainable business drivers going forward
mRNA is expected to be one of our sustainable business drivers going forward • Adds another potential treatment modality to our armamentarium for vaccines and therapeutics, across our therapeutic areas • Our Lightspeed methodology & internal cultural changes resulted in the acceleration of the platf
Slide 5: mRNA - Where we've come from
mRNA - Where we’ve come from Comirnaty >3B Hired first Pfizer internal Pfizer / BioNTech COVID-19 doses produced & mRNA experts collaboration signed 2.6B shipped, Had identified mRNA as an important BNT162b2 Vx uses an Acuitas BNT162b2 Ph3 adult trial ComirnatyTM (BNT162b2) including 1B to low- & ne
Slide 6: Our vision of mRNA leadership
Our vision of mRNA leadership Harness the power of mRNA to address the greatest unmet needs for patients with breakthrough medicines that contribute substantially to Pfizer’s growth targets by 2025 and beyond Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan
Slide 7: Pfizer's mRNA Strategy Roadmap
Pfizer’s mRNA Strategy Roadmap Harness the power of mRNA to address the greatest unmet needs for patients with breakthrough medicines Invest to Strengthen Grow Prophylactic Pursue Additional TAs with Explore opportunities in Core Franchise Vaccines* Strongest Benefit/Risk larger indications COVID-19
Slide 8: To advance our mRNA strategy, we are pursuing four agreements
To advance our mRNA strategy, we are pursuing four agreements aligned with our strategic priorities 1 2 Collaboration agreement to co-develop Collaboration for 3 Rare Diseases mRNA Shingles (HZV) Vaccine (CNS, muscular, liver) 3 4 Collaboration & Option to non-exclusively license Research collaborat
Slide 9: New collaborations established to advance mRNA programs in vaccines and rare diseases
New collaborations established to advance mRNA programs in vaccines and rare diseases Grow Prophylactic Explore Additional TAs with Focus Area Vaccines Strongest Risk/Benefit Partnership Agreement to co-develop Collaboration for 3 Rare mRNA Shingles (VZV) Vaccine Diseases (CNS, muscular, liver) • Ca
Slide 10: Formulation and manufacturing partnerships to accelerate efforts in core disease areas
Formulation and manufacturing partnerships to accelerate efforts in core disease areas Formulation Manufacturing Focus Area Access improved nanoparticle structure to Produce high-quality medicines at scale with optimize stability, targeting & efficacy efficient production processes Partnership Colla
Slide 11: Pfizer is uniquely positioned to be a leader in mRNA
Pfizer is uniquely positioned to be a leader in mRNA Strong development expertise in mRNA Deep understanding of disease within technology from Comirnaty our five core therapeutic areas • Vaccine expertise & infrastructure built • Building our internal mRNA platform to improve through development of
Slide 12: Our approach to collaborating with the ecosystem to co-create innovation
Our approach to collaborating with the ecosystem to co-create innovation Pfizer Ventures RNA Incubator Monitors early-stage companies for investment Establishes academic collaborations and initiates opportunities aligned with our mRNA strategy exploratory projects through Pfizer’s Center for Therape
Slide 13: BioNTech Shingles mRNA Vaccine Collaboration
BioNTech Shingles mRNA Vaccine Collaboration Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 13
Slide 14: What is Shingles / Herpes Zoster?
What is Shingles / Herpes Zoster? Painful disease with potentially severe & long-lasting effects in older & immunocompromised adults • Reactivation of virus that causes Chicken Pox which has been dormant in nerve endings since childhood infection • 1 in 3 US adults will experience Shingles at least
Slide 15: Opportunity for an Improved Shingles Vaccine Using mRNA Technology
Opportunity for an Improved Shingles Vaccine Using mRNA Technology Builds upon prior Pfizer-BioNTech collaboration for COVID-19 Potential mRNA VZV* Vaccine Could Allow: Maintaining High Efficacy + Reduced Side Effects + Robust, Scalable Manufacturing • Leverages Pfizer’s depth in Vaccines ($6.6B in
Slide 16: Currently Licensed Adjuvanted Recombinant Vaccine
Currently Licensed Adjuvanted Recombinant Vaccine Currently Licensed Vaccine – Effective but we believe tolerability & capacity-constrained supply can be improved • Vaccine is highly effective (up to >90% in preventing attacks*) according to data from their label, but • Large portions of prevalent a
Slide 17: Beam Therapeutics Rare Disease Base Editing Collaboration
Beam Therapeutics Rare Disease Base Editing Collaboration Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 17
Slide 18: Beam's Base Editing Platform for Rare Diseases Advances Pfizer's Path to Leadership in mRNA
Beam’s Base Editing Platform for Rare Diseases Advances Pfizer’s Path to Leadership in mRNA • Leverages Pfizer’s depth in gene therapy & rare diseases • Pfizer has 3 AAV-based* gene therapies for Rare Diseases in Phase 3 trials and 12 in pre-clinical development with 1-2 INDs expected annually • Pfi
Slide 19: Base editing is a highly differentiated, potentially best-in-class gene editing technology
Base editing is a highly differentiated, potentially best-in-class gene editing technology Therapeutic consists of BE mRNA, guide RNA and LNP ABE = Adenine Base Editor, DSPC = DiStearoylPhosphatidylCholine, PEG= PolyEthylene Glycol Breakthroughs that change patients’ lives 40th Annual JP Morgan Heal
Slide 20: Acuitas LNP Option Agreement
Acuitas LNP Option Agreement Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 20
Slide 21: Acuitas LNP Collaboration
Acuitas LNP Collaboration Acuitas Collaboration Terms Why are LNPs important for mRNA delivery? • Acuitas is one of the global leaders in development of • Engineered LNPs allow efficient intracellular delivery of LNPs mRNA vaccines/medicines to the cytoplasm • Allows Pfizer to explore LNPs for a var
Slide 22: Codex DNA Synthetic DNA Collaboration
Codex DNA Synthetic DNA Collaboration Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 22
Slide 23: Codex DNA's technology may allow significant time savings at front-end of mRNA production
Codex DNA’s technology may allow significant time savings at front-end of the mRNA production process by moving from biologic to synthetic DNA assembly, potentially reducing time from several weeks to days Codex DNA replaces these steps Breakthroughs that change patients’ lives Source for illustrati
Slide 24: mRNA Collaborations - Key Takeaways
mRNA Collaborations - Key Takeaways New BioNTech, Beam, Acuitas and Codex DNA collaborations allow Pfizer to continue to advance its mRNA strategy • These strategic collaborations provide many of the key enabling technologies needed to deepen and expand Pfizer's mRNA development • Beam expands the u
Slide 25: 40th Annual JP Morgan Healthcare Conference
40th Annual JP Morgan Healthcare Conference Breakthroughs that change patients’ lives 40th Annual JP Morgan Healthcare Conference – Jan 10, 2022 25
Pfizer — 40th Annual J.P. Morgan Healthcare Conference 2022 on 6ix